Page 66 - 《中国药房》2021年20期
P. 66

多西他赛 PELGE 纳米粒的处方优化、表征及其体外释放和抗肿

        瘤活性的初步评价                     Δ


               1*
        廖龙飞 ,杨青青 ,漆婷婷 ,邱 悦 ,肖洪涛 (1.四川省肿瘤医院/四川省癌症防治中心/电子科技大学医学院
                                         1
                        2
                                 1
                                                 1 #
        附属肿瘤医院临床药学部,成都 610041;2.国家知识产权局专利局专利审查协作四川中心,成都 610200)
        中图分类号 R943;R944.9          文献标志码     A      文章编号     1001-0408(2021)20-2492-07
        DOI   10.6039/j.issn.1001-0408.2021.20.10
        摘   要   目的:优化多西他赛(DTX)-聚乙二醇-(聚乳酸-羟基乙酸)-聚乙二醇三嵌段共聚物(PELGE)-纳米粒(NPs)的处方,对其
        进行表征,并评价其体外释放特性及抗肿瘤活性。方法:采用开环共聚法合成 PELGE,采用乳化溶剂挥发法制备 DTX-PELGE-
        NPs;采用高效液相色谱法测定DTX-PELGE-NPs中DTX的含量;以DTX用量、PELGE用量、泊洛沙姆188浓度为自变量,包封率
        为因变量,采用Box-Behnken设计-响应面法优化处方;采用激光粒度仪和透射电镜测定DTX-PELGE-NPs的粒度和Zeta电位;以
        DTX注射液为参照,采用离心超滤法测定体外释放率;以DTX注射液不含DTX的PELGE-NPs为参照,采用噻唑蓝法考察体外细
        胞毒性。结果:最优处方为DTX用量2.80 mg,PELGE用量20.60 mg,泊洛沙姆188浓度6%。优化所得DTX-PELGE-NPs的包封
        率为(86.79±1.32)%,载药量为(10.21±0.78)%,平均粒度为(78.4±2.9)nm,多分散性指数(PDI)为(0.187±0.018),Zeta电位为
        (-20.6±1.5)mV;电镜下 DTX-PELGE-NPs 呈类球形,分布均匀。相较于 DTX 注射液(4 h 时的累积释放率约为 92.3%),
        DTX-PELGE-NPs 有明显的缓释效果(36 h 时的累积释放率约为 78.6%)。0.1~50 μg/mL 的 PELGE-NPs 对人乳腺癌细胞 MCF-7
        无明显细胞毒性(P>0.05),而0.5~10 μg/mL的 DTX-PELGE-NPs能够显著抑制人乳腺癌细胞MCF-7的生长,且作用(DTX-PELGE-
        NPs 10 μg/mL组除外)显著强于同浓度DTX注射液(P<0.05)。结论:优化所得处方工艺稳定、可行;所得DTX-PELGE-NPs粒度
        均匀,包封率较高,缓释效果明显,体外抗肿瘤活性强于DTX注射液。
        关键词     多西他赛;聚乙二醇-(聚乳酸-羟基乙酸)-聚乙二醇三嵌段共聚物;Box-Behnken设计-响应面法;高效液相色谱法;处方
        优化
        Formulation Optimization and Characterization of Docetaxel PELGE Nanoparticles and Preliminarily
        Evaluation of Its Drug Release and Antitumor Activity in vitro
                                                             1
                                                   1
                                      2
        LIAO Longfei ,YANG Qingqing ,QI Tingting ,QIU Yue ,XIAO Hongtao(1. Dept. of Clinical Pharmacy,
                                                                             1
                     1
        Sichuan Cancer Hospital/Sichuan Cancer Prevention and Control Center/the Affiliated Cancer Hospital of
        University of Electronic Science and Technology of China,Chengdu 610041,China;2. Patent Examination
        Cooperation Sichuan Center,the Patent Office of CNIPA,Chengdu 610200,China)
        ABSTRACT    OBJECTIVE:To optimize the formulation of docetaxel (DTX)-mPEG-PLGA-mPEG (PELGE)-nanoparticles
        (NPs),and to characterize it and evaluate its in vitro drug release and antitumor activity. METHODS:PELGE were synthesized by
        ring-opening polymerization. DTX-PELGE-NPs were prepared by using emulsion solvent evaporation method. The content of DTX
        in DTX-PELGE-NPs was determined by HPLC. Box-Behnken design-response surface methodology was applied to optimize the
        formulation of the nanoparticles using the amount of DTX,PELGE and poloxamer 188 as independent variable,using entrapped
        efficiency as dependent variable. The particle size and Zeta-potential of DTX-PELGE-NPs were characterized by laser particle size
        analyzer and transmission electron microscope. The in vitro release of the DTX-PELGE-NPs was investigated by ultra-filtered
        centrifugation,using DTX injection as reference. In vitro cytotoxicity of the DTX-PELGE-NPs was investigated by MTT assay,
        using DTX and PELGE-NPs without DTX as reference. RESULTS:The optimal formulation included 2.80 mg DTX,20.60 mg
        PELGE and 6% poloxamer 188. The entrapped efficiency of optimized DTX-PELGE-NPs was (86.79 ± 1.32)% ;drug-loading
        amount was(10.21±0.78)%,and average particle size was(78.4±2.9)nm;polydispersity coefficient was(0.187±0.018)and
                                                            Zeta potential was (- 20.6 ± 1.5) mV. Furthermore,DTX-
            Δ 基金项目:四川省医学重点学科(实验室)及重点专科立项建设
                                                            PELGE-NPs showed a regular spherical and uniform distribution
        项目(No.川卫发〔2019〕30 号);四川省预防医学会静脉药物配制科研
                                                            under scanning electron microscopy. Compared with DTX
        (孵化)项目(No.川预学〔2020〕135号)
            *主管药师,硕士。研究方向:药剂学。电话:028-85420987。              injection(accumulative release rate of 92.3% at 4 h),DTX-
        E-mail:799583718@qq.com                             PELGE-NPs had a significant sustained-release effect(accumu-
            # 通信作者:研究员,博士。研究方向:医院药学。电话:028-                 lative release rate of 78.6% at 36 h). 0.1-50 μg/mL PELGE-NPs
        85420338。E-mail:xht927@163.com                      had no obvious cytotoxicity to human breast cancer cells


        ·2492 ·  China Pharmacy 2021 Vol. 32 No. 20                                 中国药房    2021年第32卷第20期
   61   62   63   64   65   66   67   68   69   70   71